Figure 2
From: MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
ERK1/2 pathway is activated after TKI-resistance in vitro. (a) Dose-response curve of sensitive or resistant (R) MOLM-13 cells. The IC50 value for sorafenib was almost 300 times higher than the control IC50 value in MOLM-13R cells. (b) pERK/ERK protein levels measured by western blotting in sensitive and resistant MOLM-13 cultures. The intensity of each band was normalized to the corresponding α-tubulin value. *P ≤ 0.05. (c) pERK/ERK levels of proliferative MOLM-13 cultures stained with CFDA-SE and sorted after 48 h of sorafenib treatment. pERK and ERK levels were analyzed by western blotting and normalized to α-tubulin. *P ≤ 0.05.
